Page 1889 - Hall et al (2015) Principles of Critical Care-McGraw-Hill

2 References

30. Barnes J. Quality, efficacy and safety of complementary medi- 51. Abe R, Shimizu T, Shibaki A, et al. Toxic epidermal necrolysis
cines: fashions, facts and the future. Part II: efficacy and safety. and Stevens-Johnson syndrome are induced by soluble fas
Br J Clin Pharmacol. 2003;55:331. ligand. Am J Pathol. 2003;162:1515.
31. Ernst E. Harmless herbs? A review of the recent literature. Am J 52. Roujeau JC, Guillaume JC, Fabre JP, et al. Toxic epidermal
Med. 1998;104:170. necrolysis (Lyell syndrome), incidence and drug etiology in
32. Meredith MJ. Herbal nutriceuticals: a primer for dentists and France, 1981–1985. Arch Dermatol. 1990;126:37.
dental hygienists. J Contemp Dent Pract. 2001;2:1. 53. Roupe G, Ahlmen M, Fagerberg B, et al. Toxic epidermal necrol-
33. Kahn JM, Kress JP, Hall JB. Skin necrosis after extravasation of ysis with extensive mucosal erosions of the gastrointestinal and
low-dose vasopressin administered for septic shock. Crit Care respiratory tracts. Int Arch Allergy Appl Immunol. 1986;80:145.
Med. 2002;30:1899. 54. Frenia ML, Schauben P. Use of silver sulfadiazine in Stevens-
34. Sirinek KR, Levine BA. High-dose vasopressin for acute variceal Johnson syndrome. Ann Phramacother. 1994;28:736.
hemorrhage. Clinical advantages without adverse effects. Arch 55. Heimbach DM, Engrav LH, Marvin JA, et al. Toxic epidermal
Surg. 1988;123:876. necrolysis. A step forward in treatment. JAMA. 1987;257:2171.
35. Korenberg RJ, Landau-Price D, Penneys NS. Vasopressin- 56. Fine JD. Management of acquired bullous skin diseases. N Engl
induced bullous disease and cutaneous necrosis. J Am Acad J Med. 1995;333:1475.
Dermatol. 1986;15(2, pt 2):393. 57. Stables GI, Lever RS. Toxic epidermal necrolysis and systemic
36. Kim EH, Lee SH, Byun SW, et al. Skin necrosis after a low-dose corticosteroids. Br J Dermatol. 1993;128:357.
vasopressin infusion through a central venous catheter for 58. Rzany B, Mockenhaupt M, Baur S, et al. Epidemiology of
treating septic shock. Korean J Intern Med. 2006;21(4):287-290. erythema exudativum multiforme majus, Stevens-Johnson
37. Dünser MW, Mayr AJ, Tür A, et al. Ischemic skin lesions as a syndrome, and toxic epidermal necrolysis in Germany (1990–
complication in catecholamine-resistant vasodilatory shock: 1992): structure and results of a population-based registry.
incidence and risk factors. Crit Care Med. 2003;31:1394. J Clin Epidemiol. 1996;49:769.
38. Speeckaert MM, Speeckaert R, Lambert J, Brochez L. Acute 59. Halebian PH, Madden MR, Finklestein JL, et al. Improved burn
generalized exanthematous pustulosis: an overview of the clini- center survival of patients with toxic epidermal necrolysis man-
cal, immunological and diagnostic concepts. Eur J Dermatol. aged without corticosteroids. Ann Surg. 1986;204:503.
20(4):425-433. Epub 2010 June 14. 60. Guibal F, Bastuji-Garin S, Chosidow O, et al. Characteristics of
39. Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk toxic epidermal necrolysis in patients undergoing long-term
of Stevens-Johnson syndrome or toxic epidermal necrolysis. glucocorticoid therapy. Arch Dermatol. 1995;131:669.
N Engl J Med. 1995;333:1600. 61. Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epider-
40. Bachot N, Roujeau JC. Physiopathology and treatment of mal necrolysis by blockade of CD95 with human intravenous
severe drug eruptions. Curr Opin Allergy Clin Immunol. immunoglobulin. Science. 1998;282:490.
2001;1:293. 62. Stella M, Cassano P, Bollero D, et al. Toxic epidermal necroly-
41. Becker DS. Toxic epidermal necrolysis. Lancet. 1998;351:1417. sis treated with intravenous high-dose immunoglobulins: our
42. Garcia-Doval I, LeCleach L, Bocquet H, et al. Toxic epider- experience. Dermatology. 2001;203:45.
mal necrolysis and Stevens-Johnson syndrome. Does early 63. Prins C, Kerdel FA, Padilla RS, et al. for the TEN-IVIG Study
withdrawal of causative drugs decrease the risk of death? Arch Group. Treatment of toxic epidermal necrolysis with high-dose
Dermatol. 2000;136:323. intravenous immunoglobulins: multicenter retrospective analy-
43. Murphy JT, Purdue GF, Hunt JL. Toxic epidermal necrolysis. sis of 48 consecutive cases. Arch Dermatol. 2003;139:26.
J Burn Care Rehabil. 1997;18:417. 64. Trent JT, Kirsner RS, Romanelli P, Kerdel FA. Analysis of intra-
44. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to venous immunoglobulin for the treatment of toxic epidermal
drugs. N Engl J Med. 1994;331:1272. necrolysis using SCORTEN: the University of Miami experi-
45. Ducic I, Shalom A, Rising W, et al. Outcome of patients with ence. Arch Dermatol. 2003;139:39.
toxic epidermal necrolysis syndrome revisited. Plast Reconstr 65. Shiohara T, Inaoka M, Kano Y. Drug-induced hypersensitivity
Surg. 2002;110:768. syndrome (DIHS): a reaction induced by a complex inter-
46. Bastuji-Garin S, Fouchard N, Bertocchi M, et al. SCORTEN: a play among herpesvirus and antiviral and antidrug immune
severity-of-illness score for toxic epidermal necrolysis. J Invest. responses. Allergol Int. 2006;55:1-8.
2000;115:149-153. 66. Gruchalla RS. Allergic disorders 10. Drug allergy. J Allergy Clin
47. Tay YK, Huff JC, Weston WL. Mycoplasma pneumoniae Immunol. 2003;111(suppl):S548.
infection is associated with Stevens-Johnson syndrome, not 67. Descamps V, Valance A, Edlinger C, et al. Association of her-
erythema multiforme (von Hebra). J Am Acad Dermatol. pes virus 6 infection with drug reaction with eosinophilia and
1996;35(5, pt 1):757. systemic symptoms. Arch Dermatol. 2001;137:301.
48. Nagata S. Apoptosis by death factor. Cell. 1997;88:355. 68. Kurzock R, Cohen PR. Mucocutaneous paraneoplastic manifes-
49. Iwai K, Miyawaki T, Takizawa T, et al. Differential expression tations of hematologic malignancies. Am J Med. 1995;99:207.
of bcl-2 and susceptibility to anti-Fas-mediated cell death in 69. Ruocco V, Sacerdoti G. Pemphigus and bullous pemphigoid due
peripheral blood lymphocytes, monocytes, and neutrophils. to drugs. Int J Dermatol. 1991;30:307.
Blood. 1994;84:1201. 70. Scully C, Paes De Almeida O, Porter SR, Gilkes JJ. Pemphigus
50. Tanaka M, Suda T, Haze K, et al. Fas ligand in human serum. vulgaris: the manifestations and long-term management of
Nat Med. 1996;2:317. 55 patients with oral lesions. Br J Dermatol. 1999;140:84.

Section11-O-Ref.indd 2 12/10/2014 8:08:30 PM